The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Vyome Holdings to Present Phase 2 Data for VT-1953 at AACR 2026

Key Facts

1Vyome Holdings will present Phase 2 study results for VT-1953 at the AACR 2026 Annual Meeting.

2The VT-1953 treatment targets malodor and other symptoms of Malignant Fungating Wounds (MFW).

Vyome Holdings (Nasdaq: HIND) announced it will present full results from its Phase 2 study of VT-1953 at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The drug candidate is specifically designed to treat malodor and other distressing symptoms associated with Malignant Fungating Wounds (MFW). In addition to the clinical data, the company plans to showcase preclinical findings for the treatment during the event. This presentation represents a significant milestone for the biotech firm as it seeks to address critical unmet needs in oncology care. Clinical trial updates at major industry conferences often serve as key catalysts for investor interest, and the market will be closely watching the efficacy and safety profile of VT-1953.

Create Free Account